Patients who are prescribed antibiotics during immune checkpoint blockade therapy for solid tumors face a heightened risk for ...
A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...
In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...
A research team from the National Center for Nanoscience and Technology of the Chinese Academy of Sciences, in collaboration with Chongqing Medical University, has developed three types of ...
The results of a newly reported study may offer scientists a strategy for mitigating the negative side effects associated with intravenous injection of nanoparticles used in medicine. The new approach ...
-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued ...
The FDA has approved AstraZeneca’s danicopan (Voydeya) as add-on therapy to C5-targeted antibodies for extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback